Home LiteratureArticle Details
PMID: 14702107 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo.

The Journal of clinical investigation ·Vol. 113 ·No. 1 ·2004-01-00 ·Pages 38-48

Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, Hempstead B, Mark WH, Hajjar KA

Abstract

A central tenet of fibrinolysis is that tissue plasminogen activator-dependent (t-PA- dependent) conversion of plasminogen to active plasmin requires the presence of the cofactor/substrate fibrin. However, previous in vitro studies have suggested that the endothelial cell surface protein annexin II can stimulate t-PA-mediated plasminogen activation in the complete absence of fibrin. Here, homozygous annexin II-null mice displayed deposition of fibrin in the microvasculature and incomplete clearance of injury-induced arterial thrombi. While these animals demonstrated normal lysis of a fibrin-containing plasma clot, t-PA-dependent plasmin generation at the endothelial cell surface was markedly deficient. Directed migration of annexin II-null endothelial cells through fibrin and collagen lattices in vitro was also reduced, and an annexin II peptide mimicking sequences necessary for t-PA binding blocked endothelial cell invasion of Matrigel implants in wild-type mice. In addition, annexin II-deficient mice displayed markedly diminished neovascularization of fibroblast growth factor-stimulated cornea and of oxygen-primed neonatal retina. Capillary sprouting from annexin II-deficient aortic ring explants was markedly reduced in association with severe impairment of activation of metalloproteinase-9 and -13. These data establish annexin II as a regulator of cell surface plasmin generation and reveal that impaired endothelial cell fibrinolytic activity constitutes a barrier to effective neoangiogenesis.

MeSH Terms
Animals Annexin A2/deficiency,genetics,physiology Aorta Cell Movement/physiology Cells, Cultured Collagen/physiology Endothelium, Vascular/physiology Fibrin/metabolism Homeostasis Kinetics Matrix Metalloproteinases/metabolism Mice Mice, Knockout Muscle, Smooth, Vascular/physiology Neovascularization, Pathologic/genetics Organ Specificity Vascular Endothelial Growth Factor A/physiology
Chemicals
Annexin A2 Vascular Endothelial Growth Factor A Fibrin Collagen Matrix Metalloproteinases
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Ling Qi
Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, New York 10021, USA.
Jacovina Andrew T
Deora Arunkumar
Febbraio Maria
Simantov Ronit
Silverstein Roy L
Hempstead Barbara
Mark Willie H
Hajjar Katherine A
References (63)
63 references, click to expand
  1. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity.
    J Clin Invest. 2001 Nov;108(10):1533-40 PMID: 11714745
  2. Generation and characterization of urokinase receptor-deficient mice.
    J Clin Invest. 1996 Feb 1;97(3):870-8 PMID: 8609247
  3. Neuritogenesis and the nerve growth factor-induced differentiation of PC-12 cells requires annexin II-mediated plasmin generation.
    J Biol Chem. 2001 Dec 28;276(52):49350-8 PMID: 11679580
  4. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
    J Clin Invest. 2002 Jan;109(1):101-10 PMID: 11781355
  5. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.
    FASEB J. 2002 Feb;16(2):147-54 PMID: 11818362
  6. Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin.
    J Biol Chem. 2002 Sep 13;277(37):33564-70 PMID: 12087108
  7. Plasmin induces Cyr61 gene expression in fibroblasts via protease-activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signaling pathway.
    Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1421-6 PMID: 12231560
  8. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator.
    Circulation. 2002 Oct 1;106(14):1847-52 PMID: 12356640
  9. Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity.
    J Biol Chem. 2002 Nov 22;277(47):45154-61 PMID: 12192005
  10. Degradation of connective tissue matrices by macrophages. I. Proteolysis of elastin, glycoproteins, and collagen by proteinases isolated from macrophages.
    J Exp Med. 1980 Nov 1;152(5):1340-57 PMID: 7000966
  11. Structure and composition of the inner limiting membrane of the retina. SEM on frozen resin-cracked and enzyme-digested retinas of Macaca mulatta.
    Graefes Arch Clin Exp Ophthalmol. 1986;224(4):355-60 PMID: 3710190
  12. Transforming growth factor-beta: biological function and chemical structure.
    Science. 1986 Aug 1;233(4763):532-4 PMID: 3487831
  13. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.
    EMBO J. 1990 Feb;9(2):467-74 PMID: 1689240
  14. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin.
    J Cell Biol. 1990 Apr;110(4):1361-7 PMID: 2139036
  15. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.
    Lab Invest. 1992 Oct;67(4):519-28 PMID: 1279270
  16. Angiogenic activity of fibrin degradation products is located in fibrin fragment E.
    J Pathol. 1992 Sep;168(1):47-53 PMID: 1280677
  17. A simple method of vascular endothelial cell isolation.
    Transplant Proc. 1992 Dec;24(6):2816-7 PMID: 1465952
  18. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation.
    J Biol Chem. 1993 Jun 5;268(16):11951-8 PMID: 8505319
  19. Oxygen-induced retinopathy in the mouse.
    Invest Ophthalmol Vis Sci. 1994 Jan;35(1):101-11 PMID: 7507904
  20. Physiological consequences of loss of plasminogen activator gene function in mice.
    Nature. 1994 Mar 31;368(6470):419-24 PMID: 8133887
  21. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels.
    Am J Pathol. 1994 May;144(5):855-61 PMID: 8178936
  22. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II.
    J Biol Chem. 1994 Aug 19;269(33):21191-7 PMID: 8063740
  23. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy.
    Proc Natl Acad Sci U S A. 1996 May 14;93(10):4851-6 PMID: 8643492
  24. Alternative adhesion sites in human fibrinogen for vascular endothelial cells.
    Biochemistry. 1996 Apr 2;35(13):4169-75 PMID: 8672453
  25. Ligneous conjunctivitis in plasminogen-deficient mice.
    Blood. 1998 Mar 1;91(5):1616-24 PMID: 9473227
  26. VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels.
    Exp Cell Res. 1998 Feb 1;238(2):324-34 PMID: 9473340
  27. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.
    Cancer Res. 1998 Mar 1;58(5):1048-51 PMID: 9500469
  28. Healing of corneal epithelial defects in plasminogen- and fibrinogen-deficient mice.
    Invest Ophthalmol Vis Sci. 1998 Mar;39(3):502-8 PMID: 9501859
  29. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine.
    J Biol Chem. 1998 Apr 17;273(16):9987-93 PMID: 9545344
  30. Endothelial cells in physiology and in the pathophysiology of vascular disorders.
    Blood. 1998 May 15;91(10):3527-61 PMID: 9572988
  31. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state.
    J Clin Invest. 1998 May 1;101(9):1983-91 PMID: 9576763
  32. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes.
    Cell. 1998 May 1;93(3):411-22 PMID: 9590175
  33. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice.
    J Clin Invest. 1998 Oct 15;102(8):1481-8 PMID: 9788960
  34. Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin.
    J Biol Chem. 1998 Nov 13;273(46):30719-28 PMID: 9804847
  35. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins.
    Cell. 1998 Oct 30;95(3):365-77 PMID: 9814707
  36. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency.
    N Engl J Med. 1998 Dec 3;339(23):1679-86 PMID: 9834305
  37. Annexin II and bleeding in acute promyelocytic leukemia.
    N Engl J Med. 1999 Apr 1;340(13):994-1004 PMID: 10099141
  38. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion.
    J Biol Chem. 1999 May 7;274(19):13066-76 PMID: 10224058
  39. Vascular-bed--specific hemostasis and hypercoagulable states.
    N Engl J Med. 1999 May 20;340(20):1555-64 PMID: 10332019
  40. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation.
    Nat Med. 1999 Sep;5(9):1010-7 PMID: 10470077
  41. A murine model of myocardial microvascular thrombosis.
    J Clin Invest. 1999 Sep;104(5):533-9 PMID: 10487767
  42. The expression of endothelial tissue plasminogen activator in vivo: a function defined by vessel size and anatomic location.
    J Cell Sci. 1997 Jan;110 ( Pt 2):139-48 PMID: 9044044
  43. A model of angiogenesis in the mouse cornea.
    Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1625-32 PMID: 8675406
  44. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.
    Cell. 1999 Oct 1;99(1):81-92 PMID: 10520996
  45. Tissue factor in health and disease.
    Thromb Haemost. 1997 Jul;78(1):759-64 PMID: 9198252
  46. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.
    Exp Eye Res. 1997 Jun;64(6):971-8 PMID: 9301478
  47. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin.
    Cell. 1997 Dec 26;91(7):917-25 PMID: 9428515
  48. Persistent corneal haze after excimer laser photokeratectomy in plasminogen-deficient mice.
    Invest Ophthalmol Vis Sci. 2000 Jan;41(1):67-72 PMID: 10634603
  49. The hemostatic system as a regulator of angiogenesis.
    J Biol Chem. 2000 Jan 21;275(3):1521-4 PMID: 10636838
  50. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.
    Am J Pathol. 2000 Feb;156(2):697-707 PMID: 10666398
  51. Extracellular matrix components in retrocorneal fibrous membrane in comparison to corneal endothelium and Descemet's membrane.
    Mol Vis. 2000 Mar 7;6:15-23 PMID: 10731515
  52. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function.
    J Biol Chem. 2000 Apr 7;275(14):10228-34 PMID: 10744708
  53. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I.
    Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4052-7 PMID: 10737763
  54. PAI-1, fibrosis, and the elusive provisional fibrin matrix.
    J Clin Invest. 2000 Dec;106(12):1441-3 PMID: 11120750
  55. Three-dimensional supramolecular organization of the extracellular matrix in human and rabbit corneal stroma, as revealed by ultrarapid-freezing and deep-etching methods.
    Exp Eye Res. 2001 Feb;72(2):123-35 PMID: 11161728
  56. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.
    Mol Biol Cell. 2001 Oct;12(10):2975-86 PMID: 11598185
  57. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation.
    J Biol Chem. 1994 Aug 19;269(33):21198-203 PMID: 8063741
  58. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.
    Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):905-9 PMID: 7846076
  59. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.
    Genes Dev. 1995 Apr 1;9(7):794-807 PMID: 7705657
  60. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility.
    J Biol Chem. 1995 Jul 14;270(28):16886-94 PMID: 7622505
  61. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
    Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10457-61 PMID: 7479819
  62. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice.
    Circulation. 1995 Nov 1;92(9):2585-93 PMID: 7586361
  63. Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery.
    Circ Res. 2001 Dec 7;89(12):1240-5 PMID: 11739291
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
2004-01-00
Pages
38-48
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC300771
Subset
IM
Grants
NHLBI NIH HHS · P01 HL046403 · United States
NHLBI NIH HHS · HL46403 · United States
NHLBI NIH HHS · HL67839 · United States
NHLBI NIH HHS · HL07423 · United States
NHLBI NIH HHS · P01 HL067839 · United States
NHLBI NIH HHS · HL42493 · United States
NHLBI NIH HHS · R01 HL042493 · United States
NHLBI NIH HHS · T32 HL007423 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com